277 related articles for article (PubMed ID: 37175909)
1. The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease.
Winarto J; Song DG; Pan CH
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175909
[TBL] [Abstract][Full Text] [Related]
2. Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.
Ye J; Zheng J; Tian X; Xu B; Yuan F; Wang B; Yang Z; Huang F
Mar Drugs; 2022 Mar; 20(4):. PubMed ID: 35447899
[TBL] [Abstract][Full Text] [Related]
3. A Review of the Effects of Fucoxanthin on NAFLD.
Sayuti NH; Muhammad Nawawi KN; Goon JA; Mokhtar NM; Makpol S; Tan JK
Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111187
[TBL] [Abstract][Full Text] [Related]
4. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
5. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
6. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
7. Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity.
Kim MB; Bae M; Lee Y; Kang H; Hu S; Pham TX; Park YK; Lee JY
Nutrients; 2022 May; 14(11):. PubMed ID: 35684079
[TBL] [Abstract][Full Text] [Related]
8. Astaxanthin Alleviates Nonalcoholic Fatty Liver Disease by Regulating the Intestinal Flora and Targeting the AMPK/Nrf2 Signal Axis.
Li Y; Liu J; Ye B; Cui Y; Geng R; Liu S; Zhang Y; Guo W; Fu S
J Agric Food Chem; 2022 Aug; 70(34):10620-10634. PubMed ID: 35973099
[TBL] [Abstract][Full Text] [Related]
9. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
[TBL] [Abstract][Full Text] [Related]
10. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.
Karimi-Sales E; Ebrahimi-Kalan A; Alipour MR
Biomed Pharmacother; 2019 Jan; 109():1306-1312. PubMed ID: 30551380
[TBL] [Abstract][Full Text] [Related]
11. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
12. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice.
Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S
Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955
[TBL] [Abstract][Full Text] [Related]
13. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
14. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
Ren T; Zhu J; Zhu L; Cheng M
Nutrients; 2017 Feb; 9(3):. PubMed ID: 28264426
[TBL] [Abstract][Full Text] [Related]
15. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway.
Hur W; Lee JH; Kim SW; Kim JH; Bae SH; Kim M; Hwang D; Kim YS; Park T; Um SJ; Song BJ; Yoon SK
Int J Biochem Cell Biol; 2015 Jul; 64():265-76. PubMed ID: 25957914
[TBL] [Abstract][Full Text] [Related]
17. Anti-obesity activity of the marine carotenoid fucoxanthin.
Gammone MA; D'Orazio N
Mar Drugs; 2015 Apr; 13(4):2196-214. PubMed ID: 25871295
[TBL] [Abstract][Full Text] [Related]
18. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
19. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.
Zhou H; Ma C; Wang C; Gong L; Zhang Y; Li Y
Eur J Pharmacol; 2021 May; 898():173976. PubMed ID: 33639194
[TBL] [Abstract][Full Text] [Related]
20. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
